For the quarter ending 2025-09-30, CLYM made $17,080K in revenue. -$12,737K in net income. Net profit margin of -74.57%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 9,073 | 6,575 | ||
| Acquired in-process research and development, related party | 0 | 0 | ||
| General and administrative | 5,819 | 4,102 | ||
| Total operating expenses | 14,892 | 10,677 | ||
| Loss from operations | -14,892 | -10,677 | ||
| Interest income | 2,037 | 2,173 | ||
| Foreign currency loss | -33 | -162 | ||
| Total other income, net | 2,004 | 2,011 | ||
| Net loss | -12,888 | -8,666 | ||
| Unrealized gain on marketable securities | 151 | 32 | ||
| Comprehensive loss | -12,737 | -8,634 | ||
| Net loss per share, basic | -0.19 | -0.13 | ||
| Net loss per share, diluted | -0.19 | -0.13 | ||
| Weighted average number of shares outstanding, basic | 68,003,248 | 67,585,121 | ||
| Weighted-average number of shares outstanding, diluted | 68,003,248 | 67,585,121 | ||
Climb Bio, Inc. (CLYM)
Climb Bio, Inc. (CLYM)